Beat HIV


We welcome the following research partners to the BEAT-HIV Delaney Collaboratory:

Santiago Avila-Rios, Instituto Nacional de Enfermedades Respiratorias (INER)
Claire Deleage, National Cancer Institute Campus at Frederick
Sara Gianella-Weibel, University of California, San Diego
Stephanie Jost, Beth Israel Deaconess Medical Center
Hans-Peter Kiem, Fred Hutchinson Cancer Research Center
Daniel Kuritzkes, Brigham & Women’s Hospital
Alan Landay, Rush University
Christopher Peterson, Fred Hutchinson Cancer Research Center
Keith Reeves, Duke University
Eileen Scully, Johns Hopkins University School of Medicine
Davey Smith, University of California, San Diego
Golnaz Vahedi, University of Pennsylvania
Drew Weissman, University of Pennsylvania

Click here to read our press release.

What is the BEAT-HIV Delaney Collaboratory?

The Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) is a consortium of more than 60 top HIV researchers from leading academic research institutions working with government, nonprofit organizations, and industry partners to test combinations of several novel immunotherapies under new preclinical research and clinical trials.

The BEAT-HIV Collaboratory has three main goals:

Goal 1- Find where and how HIV hides

Even after treatment with current medications that render viral load undetectable, there are still a few cells in the body where the virus hides. In order to get rid of the virus, we need to find where and how it hides; then we can try to force it out and destroy it.

Goal 2- Make the immune system stronger against HIV

By using a medication called Pegylated Interferon Alpha 2b, which may help control viruses, in combination with antibodies that can neutralize HIV, we may be able to reduce the number of cells containing hidden HIV. This could bring us much closer to developing a cure.

Goal 3- Introduce new HIV “killer cells”

What if we were able to give a patient special cells that would actually seek out and kill the cells in which HIV hides? Some previous studies have already done something similar, but these “killer cells” became infected themselves. With the BEAT-HIV project, we will remove a protein that facilitated HIV infection before giving these cells to the patient, making them resistant and able to destroy cells with hidden HIV.

Community States Rationale for Beat-HIV

The BEAT-HIV Delaney Collaboratory is supported by (a) NIH grant number UM1AI126620 co-funded by NIAID, NIMH, NINDS, and NIDA, and (b) The Philadelphia Foundation.